Peloton Wealth Strategists’s Neurocrine Biosciences NBIX Stock Holding History

Peloton Wealth Strategists’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.76M	Sell	13,335 -225	-2%	-$29.9K	0.71%	52
2025 Q4	$1.92M	Sell	13,560 -250	-2%	-$36.2K	0.75%	50
2025 Q3	$1.94M	Sell	13,810 -1,100	-7%	-$149K	0.76%	48
2025 Q2	$1.87M	Sell	14,910 -80	-0.5%	-$9.17K	0.75%	49
2025 Q1	$1.66M	Buy	14,990 +875	+6%	+$111K	0.69%	53
2024 Q4	$1.93M	Buy	14,115 +10,600	+302%	+$1.31M	0.78%	45
2024 Q3	$405K	Buy	+3,515	New	+$482K	0.16%	82

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peloton Wealth Strategists's NBIX Position: Q1 2026 in Review

Peloton Wealth Strategists reduced its Neurocrine Biosciences (NBIX) stake by 1.7% in Q1 2026, selling an estimated $29.9K and leaving 13,335 shares worth $1.76M. The position accounts for 0.71% of the portfolio, ranked #52.

Peloton Wealth Strategists first reported a position in NBIX in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.94M in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Peloton Wealth Strategists held 13,335 shares of Neurocrine Biosciences worth $1.76M as of Q1 2026.
Peloton Wealth Strategists sold 225 Neurocrine Biosciences shares in Q1 2026, an estimated $29.9K.
Neurocrine Biosciences made up 0.71% of Peloton Wealth Strategists's portfolio in Q1 2026, its #52 holding.
Peloton Wealth Strategists first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 7 quarters since.
Peloton Wealth Strategists's Neurocrine Biosciences position peaked at $1.94M in Q3 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Peloton Wealth Strategists's 13F filing for Q1 2026, filed 14 May 2026.